Back to search

Peptide record

TPDB09200

Ascaphin-8 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09200
Ascaphin-8
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 AI4AVP DRAVP 2.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 19-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GFKDLLKGAAKALVKTVLF
Physicochemical Analysis
C97H163N23O23
RNCEQHIMPSWY
LK
2019.50
10.55
4
1
11
+3
0.48
0.737
128.42
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
3
A
0
R
0
N
1
D
0
C
0
E
0
Q
2
G
0
H
0
I
4
L
4
K
0
M
2
F
0
P
0
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 4 K: 4 M: 0 F: 2 P: 0 S: 0 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
19
C97H163N23O23
2019.50
10.55
+3
0.48
0.737
Free
L
Not Available
Free
Antibacterial
Coastal Tailed Frog,Ascaphus truei, Pacific Northwest, USA, North America
Evidence Records 54 records
Evidence 1 Activity

Activity

MIC
Antibacterial
6 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 2 Activity

Activity

MIC
Antibacterial
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 3 Activity

Activity

MIC
Antibacterial
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 4 Activity

Activity

MIC
Antibacterial
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 5 Activity

Activity

MIC
Antibacterial
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP DRAMP

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 6 Activity

Activity

MIC
Antibacterial
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP DRAMP

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 7 Activity

Activity

MIC
Antibacterial
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP DRAMP

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 8 Activity

Activity

MIC
Antibacterial
25 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 9 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP DRAMP

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 10 Activity

Activity

Not Available
Anticancer

Target

Not Available
Not Available
Not Available

Assay & Model

Not Available
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 11 Activity

Activity

MIC
Antifungal
6 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 12 Activity

Activity

MIC
Antifungal
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 13 Activity

Activity

MIC
Antifungal
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 14 Activity

Activity

MIC
Antifungal
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 15 Activity

Activity

MIC
Antifungal
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 16 Activity

Activity

MIC
Antifungal
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 17 Activity

Activity

MIC
Antifungal
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 18 Activity

Activity

MIC
Antifungal
25 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 19 Activity

Activity

MIC
Antifungal
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 20 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 21 Activity

Activity

MIC
Antiparasitic
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 22 Activity

Activity

MIC
Antiparasitic
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 23 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 24 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP 3.0 DRAMP

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 25 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP 3.0 DRAMP

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 26 Activity

Activity

MIC
Antiparasitic
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP 3.0 DRAMP

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 27 Activity

Activity

MIC
Antiparasitic
25 µM

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 28 Activity

Activity

MIC
Antiparasitic
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP 3.0 DRAMP

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 29 Activity

Activity

MIC
Antiviral
6 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 30 Activity

Activity

MIC
Antiviral
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 31 Activity

Activity

MIC
Antiviral
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 32 Activity

Activity

MIC
Antiviral
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 33 Activity

Activity

MIC
Antiviral
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 34 Activity

Activity

MIC
Antiviral
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 35 Activity

Activity

MIC
Antiviral
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 36 Activity

Activity

MIC
Antiviral
25 µM

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 37 Activity

Activity

MIC
Antiviral
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 38 Activity

Activity

HC50
Hemolysis
50 µM
[Ref.15207717]HC50=50 µM against human erythrocytes

Target

human erythrocytes

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Biochem Biophys Res Commun. 2004 Jul 16 320(1):170-175.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 39 Activity

Activity

50% Hemolysis
Toxicity
55 µM
Hemolytic Cytotoxic
50% Hemolysis | 55 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The ascaphins: a family of antimicrobial peptides from the skin secretions of the most primitive extant frog, Ascaphus truei. | Biochem Biophys Res Commun | 2004
Evidence 40 Activity

Activity

50% Cell death
Toxicity
7 µM
Cytotoxic
50% Cell death | 7 | µM | target cell: Mouse fibroblasts L929

Target

Mouse fibroblasts L929

Source & Reference

NA
DBAASP
Design of potent, non-toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin-8 and peptide XT-7. | Chem Biol Drug Des | 2008
Evidence 41 Activity

Activity

50% Cell death
Toxicity
2.9 µM
Cytotoxic
50% Cell death | 2.9 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 42 Activity

Activity

14.72±0.79% Hemolysis
Toxicity
8 µM
Hemolytic Cytotoxic
14.72±0.79% Hemolysis | 8 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 43 Activity

Activity

28.10±4.76% Hemolysis
Toxicity
16 µM
Hemolytic Cytotoxic
28.10±4.76% Hemolysis | 16 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 44 Activity

Activity

54.35±4.5% Hemolysis
Toxicity
32 µM
Hemolytic Cytotoxic
54.35±4.5% Hemolysis | 32 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 45 Activity

Activity

91.90±6.36% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
91.90±6.36% Hemolysis | 64 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 46 Activity

Activity

100% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
100% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 47 Activity

Activity

LC90
Toxicity
64 µg/mL
Cytotoxic
LC90 | 64 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 48 Activity

Activity

50% Hemolysis
Toxicity
>200 µM
Hemolytic Cytotoxic
50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The ascaphins: a family of antimicrobial peptides from the skin secretions of the most primitive extant frog, Ascaphus truei. | Biochem Biophys Res Commun | 2004
Evidence 49 Activity

Activity

10% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 50 Activity

Activity

LC
Toxicity
128 µg/mL
Cytotoxic
LC | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 51 Activity

Activity

LC90
Toxicity
128 µg/mL
Cytotoxic
LC90 | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 52 Activity

Activity

LC50
Toxicity
100 µg/mL
Cytotoxic
LC50 | 100 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 53 Activity

Activity

HC50
Toxicity
50 µM
Hemolytic
Hemolytic_activity: [Ref.15207717]HC50=50 µM against human erythrocytes

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochem Biophys Res Commun. 2004 Jul 16 320(1):170-175.
Evidence 54 Hemolysis

Activity

50 µM
HC50
[Ref.15207717]HC50=50 µM against human erythrocytes
Hemolysis

Target

human erythrocytes

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
Biochem Biophys Res Commun. 2004 Jul 16 320(1):170-175.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.